Evaluating Clinical Safety and Analytical Impact of Subvisible Silicone Oil Particles in Biopharmaceutical Products评估生物制药产品中可见硅油颗粒的临床安全性和分析影响JOURNAL OF PHARMACEUTICAL SCIENCESIF3.82024-05-012PRE
CMC Regulatory Considerations for Antibody-Drug Conjugates抗体-药物偶联物的CMC监管注意事项JOURNAL OF PHARMACEUTICAL SCIENCESIF3.82023-12-017PRE
Not the Usual Suspects: Alternative Surfactants for BiopharmaceuticalsACS APPLIED MATERIALS & INTERFACESIF8.22023-07-148PRE
Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics(vol 25, 6, 2023)AAPS JOURNALIF3.72023-01-111OA
The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - Part 1: Higher molecular weight species and subvisible particle formationinternational journal of pharmaceuticsIF6.42022-12-0111OAAI
The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - part 2: Aggregate formation and oxidationinternational journal of pharmaceuticsIF6.42022-12-0111OAAI
Evaluation of Two Novel Scale-Down Devices for Testing Monoclonal Antibody Aggregation During Large-Scale FreezingJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82022-07-013PRE
Scaling Down Large-Scale Thawing of Monoclonal Antibody Solutions: 3D Temperature Profiles, Changes in Concentration, and Density GradientsPHARMACEUTICAL RESEARCHIF4.32021-11-027OAAI
Cryoconcentration and 3D Temperature Profiles During Freezing of mAb Solutions in Large-Scale PET Bottles and a Novel Scale-Down DevicePHARMACEUTICAL RESEARCHIF4.32020-08-3012PREAI
Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on StabilityJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82020-01-0134OAAI
Oxidation-Induced Destabilization of Model Antibody-Drug ConjugatesJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82019-03-0124PREAI